Hello Doctor, my mother has ovarian cancer and has completed 4 cycles of neoadjuvant chemotherapy with very good response (CA-125 reduced from 273 to 11). Her treating team is now planning interval cytoreductive surgery with HIPEC.
We would like to take an expert opinion specifically regarding whether HIPEC is truly necessary/beneficial in her case, considering the additional recovery burden and cost. Could you please help us in deciding if HIPEC would be necessary and effective ?
Thank you.
Hello Doctor,
Seeking your opinion regarding a 71-year-old patient diagnosed with NSCLC favor squamous cell carcinoma (P40 diffuse positive, TTF1 negative) involving the right upper lobe. PET-CT shows a spiculated RUL lesion approx. 3.0 × 4.7 × 4.0 cm with SUV max 16.58. Mildly FDG-avid hilar/paratracheal nodes (SUV ~4.2) with some calcification noted. EBUS/TBNA from stations 4R, 7 and 11L showed no evidence of malignancy. Current staging documented as cT2bN1M0 (Stage IIB). Proposed plan is neoadjuvant chemotherapy followed by reassessment for surgery.
Would appreciate guidance on:
1. Whether chemo + surgery appears the optimal curative-intent approach in this case.
2. Whether adding immunotherapy to neoadjuvant chemotherapy would significantly improve outcomes.
3. Whether current imaging/EBUS findings sufficiently support N1 staging or need further nodal evaluation.
Thank you.
Can OSMF still progress even after quitting the habit, and will there still be any kind of cancer risk?
Hello doctor my father is 75 yrs old.. from last 4 years he diagnosed with ckd but before 2 months his hb level very low. But now his condition is better but hb is 8 and platelets is 65000 his creatinine level is 5 . 15 and other 2 reports I attach.. so please tell me is my father have blood cancer?
Seeking expert opinion for a 62F with signet ring cell carcinoma of sigmoid colon diagnosed July 2025. She underwent surgery (LAR + hysterectomy + BSO) followed by chemotherapy (Dacotin + Capecitabine). Latest PET-CT Feb 2026 shows no liver, lung, brain metastasis and no residual primary lesion. However, there are FDG-avid peritoneal nodules (SUV ~7) with mild ascites, suggestive of post-op changes vs residual disease. Kindly advise on further management, chemotherapy strategy, CRS alone or CRS with HIPEC suitability or second line chemo.
